NSE: INDGN· Info TechValue · Aug 26Small cap

Indegene

Pharma commercialisation outsourcing

Last close
₹605.15
29 Sept 2026 · reference
1D · 1M
−1.3% · +4.5%
price-only
Weight
1.2%
31 Jul 2026 · Aug rank 25
Thesis review
8 Sep 2026
Why We Own, p48
Coverage owner: Research (per book); latest results Q Jun-26Screener ↗Tijori ↗NSE ↗
Map

What must happen → what could break it → what we watch

Catalysts · 3
  • Q3FY27 (Jan-2027): revenue recognition begins on the USD 10 mn+ ACV outcome-based omnichannel contract.
    C1
  • Q4FY27 (Apr/May-2027): EBITDA margin back in the 19-20% band per guidance.
    C2
  • Further tuck-in acquisitions using Rs 1,460 cr cash; expansion of the 'Tectonic' largest-client engagement from Germany/Spain to more markets.
    C3
Material risks · 3
  • Client concentration: top-20 clients 72% of FY26 revenue; largest client >USD 50 mn run-rate; US drug-pricing/MFN policy cuts to pharma marketing budgets would hit demand.
    R1
  • Margin execution: EBITDA margin fell from ~20% to 16.9%; employee costs +37% YoY; failure to reach 19-20% by Q4FY27 would compress the multiple.
    R2
  • AI commoditisation of content/medical-writing workflows, and slower enterprise AI adoption than expected (flagged by management); acquisition integration (BioPharm USD 104 mn) and FX (75% North America).
    R3
Live monitors
  • Valuation vs approved target
    No target stated
  • Latest reported quarter
    Q Jun-26
  • Results-driven thresholds
    Awaiting approved numbers

Catalysts and risks are the approved one-pager text in full; the register below adds owners and review dates. Monitors read from the price and fundamentals feeds.

Risks as a decision framework

Material risks

Risk register
#Risk (approved text)Owner · next review
01Client concentration: top-20 clients 72% of FY26 revenue; largest client >USD 50 mn run-rate; US drug-pricing/MFN policy cuts to pharma marketing budgets would hit demand.Research · post 2QFY27
02Margin execution: EBITDA margin fell from ~20% to 16.9%; employee costs +37% YoY; failure to reach 19-20% by Q4FY27 would compress the multiple.Research · post 2QFY27
03AI commoditisation of content/medical-writing workflows, and slower enterprise AI adoption than expected (flagged by management); acquisition integration (BioPharm USD 104 mn) and FX (75% North America).Research · post 2QFY27

Exposure mechanism, impact and mitigants are as written in the book. Leading indicators and numeric triggers not stated in the approved text remain research tasks rather than being invented.

Catalysts

Observable events

  • 01Q3FY27 (Jan-2027): revenue recognition begins on the USD 10 mn+ ACV outcome-based omnichannel contract.
  • 02Q4FY27 (Apr/May-2027): EBITDA margin back in the 19-20% band per guidance.
  • 03Further tuck-in acquisitions using Rs 1,460 cr cash; expansion of the 'Tectonic' largest-client engagement from Germany/Spain to more markets.
Monitors

Live monitors from available data

  • ClearValuation exceeding the approved range: reference close 605 vs base target not stated.
  • DataLatest reported quarter in fundamentals: Q Jun-26. Results-driven monitors (growth below thesis threshold, margin, credit cost) need approved numeric thresholds; none in the book.
  • DataInput-cost and capital-allocation monitors require licensed commodity/filings feeds — not configured.